Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: what to expect in the near future
Cet article analyse les enjeux liés au développement et à l'utilisation des immunothérapies dans un contexte néoadjuvant chez des patients atteints d'un cancer urothélial
Highlights : •The localized muscle-invasive bladder cancer scenario remains challenging since therecurrence rate continues to be high despite all therapeutic efforts. •The advent of immune checkpoint inhibitors (ICIs) has completely transformed the treatmentlandscape of bladder cancer. •The emerging data from the different trials exploring the role of ICIs in the neoadjuvantsetting of urothelial cancer are promising. •The complete response rates observed might lead to a change in the neoadjuvant scenarioand set new treatment standards. •There is a need for further randomized clinical trials and associated biomarker profilesfor better patientś selection.